dc.contributor.author |
Whisenant, Jonathan |
|
dc.contributor.author |
Burgess, Kevin |
|
dc.date.accessioned |
2020-11-26T02:40:16Z |
|
dc.date.available |
2020-11-26T02:40:16Z |
|
dc.date.issued |
2020 |
|
dc.identifier.citation |
ACS Med. Chem. Lett. 2020, 11, 1076−1078 |
en_US |
dc.identifier.uri |
${sadil.baseUrl}/handle/123456789/136 |
|
dc.description |
3 p. |
en_US |
dc.description.abstract |
Recent crystal structure data for protein−protein interactions featuring the SARS-CoV-2 spike protein will inevitably trigger a new wave of research in this area that was not possible before. This Viewpoint outlines a few of the ways that it is already happening. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
ACS Medicinal Chemistry Letters |
en_US |
dc.subject |
SARS-CoV-2 |
en_US |
dc.subject |
spike protein |
en_US |
dc.subject |
peptide |
en_US |
dc.subject |
monoclonal antibody |
en_US |
dc.title |
Blocking Coronavirus 19 Infection via the SARS-CoV‑2 Spike Protein: Initial Steps |
en_US |
dc.type |
Article |
en_US |